ECB-ART-50119
Curr Oncol
2012 Jun 01;19Suppl 1:S24-32. doi: 10.3747/co.19.1058.
Show Gene links
Show Anatomy links
The role of molecular pathology in non-small-cell lung carcinoma-now and in the future.
Brandao GD
,
Brega EF
,
Spatz A
.
???displayArticle.abstract???
In recent years, better understanding of the molecular biology of non-small-cell lung carcinoma (nsclc) has led to a revolution in the work-up of these neoplasms. As a pathology diagnosis, "nsclc" without further attempt at subclassification is no longer accepted as a standard of care; separating squamous cell carcinoma from adenocarcinoma and large-cell carcinoma carries implications for prognosis and treatment decisions. Currently, detection of the presence in nsclc of mutations involving the epidermal growth factor receptor (EGFR) gene and fusion of the N-terminal portion of the protein encoded by EML4 (echinoderm microtubule-associated protein-like 4 gene) with the intracellular signaling portion of the receptor tyrosine kinase encoded by ALK (anaplastic lymphoma kinase gene)-that is, EML4-ALK-and variants has become routine in many centres because patients having tumours harbouring such alterations might benefit from tyrosine kinase inhibitors as part of their treatment regimen.The purpose of the present review is to highlight important aspects of the screening for molecular derangements in nsclc and to briefly discuss the emergence of possible future biomarkers.
???displayArticle.pubmedLink??? 22787408
???displayArticle.pmcLink??? PMC3377751
???displayArticle.link??? Curr Oncol
References [+] :
Amado,
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
2008, Pubmed
Amado, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. 2008, Pubmed
Asano, Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. 2006, Pubmed
Aviel-Ronen, K-ras mutations in non-small-cell lung carcinoma: a review. 2006, Pubmed
Bell, Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. 2008, Pubmed
Billah, EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. 2011, Pubmed
Blons, Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. 2006, Pubmed
Boland, Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. 2009, Pubmed
Brose, BRAF and RAS mutations in human lung cancer and melanoma. 2002, Pubmed
Brugger, Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. 2011, Pubmed
Camidge, Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. 2010, Pubmed
Capella, Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. 1991, Pubmed
Choi, Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. 2008, Pubmed
Chowdhuri, EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. 2012, Pubmed
Cohen, Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. 2006, Pubmed
Cohen, A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). 2007, Pubmed
Davies, Mutations of the BRAF gene in human cancer. 2002, Pubmed
Eberhard, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. 2005, Pubmed
Ellis, A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. 2011, Pubmed
Engelman, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. 2007, Pubmed
Finberg, Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. 2007, Pubmed
Graziano, Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. 1999, Pubmed
Guix, Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. 2008, Pubmed
Herbst, Lung cancer. 2008, Pubmed
Herbst, Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. 2010, Pubmed
Hernández, TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. 1999, Pubmed
Hoshi, Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. 2007, Pubmed
Ihle, Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. 2012, Pubmed
Inamura, EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. 2009, Pubmed , Echinobase
Jacobs, A review of the role of insulin-like growth factor 2 in malignancy and its potential as a modifier of radiation sensitivity. 2008, Pubmed
Jemal, Cancer statistics, 2010. 2010, Pubmed
Johnson, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. 2004, Pubmed
Kanaji, Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction. 2011, Pubmed
Karapetis, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. 2008, Pubmed
Keedy, American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. 2011, Pubmed
Kim, Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. 2011, Pubmed
Kimura, Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. 2006, Pubmed
Kobayashi, Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. 2011, Pubmed
Koivunen, EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. 2008, Pubmed
Kranenburg, The KRAS oncogene: past, present, and future. 2005, Pubmed
Kwak, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. 2010, Pubmed
Ladanyi, Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. 2008, Pubmed
Lamant, A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. 1999, Pubmed
Lawrence, TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. 2000, Pubmed
Li, The status of KRAS mutations in patients with non-small cell lung cancers from mainland China. 2009, Pubmed
Lin, Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. 2009, Pubmed , Echinobase
Liu, A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. 2011, Pubmed
Lièvre, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. 2006, Pubmed
Loriot, Are RAS mutations predictive markers of resistance to standard chemotherapy? 2009, Pubmed
Ludovini, Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. 2012, Pubmed
Maemondo, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. 2010, Pubmed
Maheswaran, Detection of mutations in EGFR in circulating lung-cancer cells. 2008, Pubmed
Mao, KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. 2010, Pubmed
Marchetti, EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 2005, Pubmed
Marchetti, Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. 2011, Pubmed
Marks, Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. 2008, Pubmed
Martelli, EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. 2009, Pubmed , Echinobase
Mascaux, The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. 2005, Pubmed
Matsukuma, Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. 2006, Pubmed
Mino-Kenudson, A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. 2010, Pubmed
Morris, Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. 1994, Pubmed
Paik, Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. 2011, Pubmed
Pan, Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. 2005, Pubmed
Pao, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 2005, Pubmed
Pao, Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. 2007, Pubmed
Pellegrini, HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. 2003, Pubmed
Pulford, Anaplastic lymphoma kinase proteins in growth control and cancer. 2004, Pubmed
Ramalingam, Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. 2011, Pubmed
Raponi, KRAS mutations predict response to EGFR inhibitors. 2008, Pubmed
Rekhtman, Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. 2011, Pubmed
Reungwetwattana, Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). 2012, Pubmed
Riely, Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. 2008, Pubmed
Rikova, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. 2007, Pubmed
Roberts, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. 2007, Pubmed
Roberts, Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? 2010, Pubmed
Rodig, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. 2009, Pubmed
Salomon, Epidermal growth factor-related peptides and their receptors in human malignancies. 1995, Pubmed
Sang, MAGE-A family: attractive targets for cancer immunotherapy. 2011, Pubmed
Scagliotti, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. 2008, Pubmed
Schubbert, Hyperactive Ras in developmental disorders and cancer. 2007, Pubmed
Shaw, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. 2009, Pubmed
Shiota, Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. 1994, Pubmed
Siegfried, Prognostic value of specific KRAS mutations in lung adenocarcinomas. 1997, Pubmed
Slebos, K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. 1990, Pubmed
Soda, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 2007, Pubmed , Echinobase
Takeuchi, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. 2009, Pubmed
Tanaka, Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. 2007, Pubmed
Thomas, High-throughput oncogene mutation profiling in human cancer. 2007, Pubmed
Thomas, Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. 2006, Pubmed
Touriol, Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). 2000, Pubmed
Travis, Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. 2011, Pubmed
Trinei, A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. 2000, Pubmed
Tsao, Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. 2007, Pubmed
Wan, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. 2004, Pubmed
Weickhardt, A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. 2012, Pubmed
Yatabe, A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. 2006, Pubmed
Zhou, Rapid detection of epidermal growth factor receptor mutations in non-small cell lung cancer using real-time polymerase chain reaction with TaqMan-MGB probes. 2006, Pubmed